Feng Qian

Assessment of the breakthrough-therapy-designated drugs granted in China: a pooled analysis 2020-2022.

Yanrong Li, Xingxian Luo, Feng Qian, 2022, Drug discovery today.

Assessment of the Delay in Novel Anticancer Drugs between China and the United States: A Comparative Study of Drugs Approved between 2010 and 2021

Xingxian Luo, Xin-Li Du, Feng Qian, 2022, Clinical pharmacology and therapeutics.

The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis

S. Chow, Yue Zhou, Xingxian Luo, 2022, The Lancet regional health. Western Pacific.

Analysis of Patent and Regulatory Exclusivity for Novel Agents in China and the United States: A Cohort Study of Drugs Approved Between 2018 and 2021

Xingxian Luo, Xin-Li Du, Jingshu Yang, 2022, Clinical pharmacology and therapeutics.